Laboratorios Rovi : Solid Q1 2022 results, somewhat ahead of estimates with sales guidance for FY maintained
>Strong growth again in Q1 2022 thanks to Moderna vaccine and Becat - Total revenues increased +58% y-o-y in Q1 2022 reaching a record level of € 206m (vs € 185m reported last Q4 2021), in line with our estimates and consensus, again showing a robust performance of the Moderna agreement on the mRNA COVID-19 vaccine (sales of toll manufacturing +167% y-o-y to € 95m, in line with expectations but showing a sequential improvement vs € 85m last quarter). There was also a ...Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.